SOLV
Solventum CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic sales growth non-GAAP | 2.1% | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SOLV
this stock
Solventum Corp
|
$13.28B | -3.2% | +0.9% | 9.4 | 2.9% |
|
ISRG
Intuitive Surgical Inc
|
$144.07B | -28.2% | +20.5% | 49.4 | 2.1% |
|
MDLN
Medline Inc.
|
$53.91B | -2.3% | +11.5% | — | 2.8% |
|
BDX
Becton Dickinson & Co
|
$41.87B | +0.9% | +8.2% | 57.7 | 4.1% |
|
ALC
Alcon Inc
|
$33.07B | -14.0% | +10.5% | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SOLV | -2.0% | -5.2% | -4.7% | -0.6% | -3.2% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -3.4% | -9.3% | -13.7% | -1.7% | -13.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.